AstraZeneca (AZN) Q3 2026 Earnings Call Transcript
AstraZeneca reported Q3 2026 earnings, with total revenue up 7% and core EPS up 14%. Excluding Farxiga and Brilinta, revenue grew 12%. The company highlighted progress in 12 Phase III programs and approvals for 4 new medicines. They remain confident in achieving $80 billion revenue by 2030. Oncology, rare disease, and R&I drove double-digit growth, offsetting losses from Farxiga and Brilinta. AstraZeneca also announced a collaboration with Summit Therapeutics.
How this was made
The 30-second read
Why it matters
The disclosed growth metrics and pipeline progress are likely to influence investor sentiment and short‑term price action.
Market read
First disclosure of Q3 performance for a large‑cap pharma, providing fresh data for traders.
What to watch
Potential headwinds from Farxiga and Brilinta loss of exclusivity and China procurement pressures.
Background
AstraZeneca presented its Q3 2026 earnings call, highlighting revenue, EPS, new drug approvals, and pipeline milestones.
Ticker impact
Q3 2026 earnings call disclosed 7% revenue growth and 14% core EPS increase, plus new product approvals and pipeline updates.
likely upward pressure as investors price in better‑than‑expected revenue and EPS growth
First‑time disclosure of Q3 results with double‑digit EPS growth and new approvals; large‑cap pharma typically reacts positively to beat expectations.
Market effects
Boosts broader pharma sector sentiment, especially peers with oncology pipelines.
Positive for European markets where AZN is a heavyweight.
May lift global healthcare indices as a leading drugmaker reports strong growth.
Counterpoint
If guidance falls short of market expectations despite growth, the stock could face disappointment.
Key entities
- companyAstraZeneca
Global pharmaceutical company reporting Q3 2026 results.
